Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.
Company profile
Ticker
MRK, MRK-FP, MRK-PE, MRK-MM
Exchange
Website
CEO
Kenneth Frazier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Merck & Co. Inc., SCHERING PLOUGH CORP
SEC CIK
Corporate docs
Subsidiaries
7728026 Canada Inc. • Abmaxis Inc. • Acceleron Pharma Inc. • Afferent Pharmaceuticals, Inc. • Agrident GmbH • Agro Verhen B.V. • Allflex Argentina S.A. • Allflex Australia • Allflex (China) Intelligent Technology Co. Ltd. • Allflex dan-mark ApS ...
IRS number
221918501
MRK stock data
Latest filings (excl ownership)
8-K
Merck Announces First-Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
10-K/A
2023 FY
Annual report (amended)
11 Apr 24
PX14A6G
Letter to shareholders
1 Apr 24
PX14A6G
Letter to shareholders
27 Mar 24
S-3ASR
Automatic shelf registration
19 Mar 24
S-3ASR
Automatic shelf registration
19 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
Transcripts
MRK
Earnings call transcript
2024 Q1
25 Apr 24
MRK
Earnings call transcript
2023 Q4
1 Feb 24
MRK
Earnings call transcript
2023 Q3
26 Oct 23
MRK
Earnings call transcript
2023 Q2
1 Aug 23
MRK
Earnings call transcript
2023 Q1
27 Apr 23
MRK
Earnings call transcript
2022 Q4
2 Feb 23
MRK
Earnings call transcript
2022 Q3
27 Oct 22
MRK
Earnings call transcript
2022 Q2
28 Jul 22
MRK
Earnings call transcript
2022 Q1
28 Apr 22
MRK
Earnings call transcript
2021 Q4
3 Feb 22
Latest ownership filings
3
Betty D Larson
8 Apr 24
4
PETER C WENDELL
29 Mar 24
4
Christine E Seidman
29 Mar 24
4
THOMAS H GLOCER
29 Mar 24
4
Mary Ellen Coe
29 Mar 24
4
Harpoon Therapeutics, Inc.
11 Mar 24
4
Caroline Litchfield
15 Feb 24
4
Robert M Davis
15 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.67 bn | 8.67 bn | 8.67 bn | 8.67 bn | 8.67 bn | 8.67 bn |
Cash burn (monthly) | (no burn) | 217.50 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 1.49 bn | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 7.17 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 33.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
52.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2809 |
Opened positions | 286 |
Closed positions | 523 |
Increased positions | 1028 |
Reduced positions | 1215 |
13F shares | Current |
---|---|
Total value | 134.74 tn |
Total shares | 1.33 bn |
Total puts | 4.68 mm |
Total calls | 2.77 mm |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 244.78 mm | $26.69 tn |
STT State Street | 116.87 mm | $12.83 tn |
Wellington Management | 85.60 mm | $9.33 tn |
FMR | 42.80 mm | $4.67 tn |
MS Morgan Stanley | 40.13 mm | $4.37 tn |
Charles Schwab Investment Management | 36.68 mm | $3.97 tn |
T. Rowe Price | 30.09 mm | $3.28 bn |
NTRS Northern Trust | 28.49 mm | $3.11 tn |
JPM JPMorgan Chase & Co. | 25.41 mm | $2.77 tn |
LGEN Legal & General | 23.49 mm | $2.56 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Wendell Peter C | Phantom Stock Common Stock | Grant | Acquire A | No | No | 131.95 | 227.359 | 30.00 k | 124,752.62 |
28 Mar 24 | Christine E Seidman | Phantom Stock Common Stock | Grant | Acquire A | No | No | 131.95 | 61.576 | 8.13 k | 12,920.107 |
28 Mar 24 | Glocer Thomas H | Phantom Stock Common Stock | Grant | Acquire A | No | No | 131.95 | 341.038 | 45.00 k | 93,360.398 |
28 Mar 24 | Coe Mary Ellen | Phantom Stock Common Stock | Grant | Acquire A | No | No | 131.95 | 227.359 | 30.00 k | 21,049.663 |
News
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
25 Apr 24
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
25 Apr 24
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
25 Apr 24
Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
25 Apr 24
Merck & Co Q1 2024 Adj EPS $2.07 Beats $1.88 Estimate, Sales $15.775B Beat $15.196B Estimate
25 Apr 24
Press releases
Merck Announces First-Quarter 2024 Financial Results
25 Apr 24
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
22 Apr 24
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
19 Apr 24
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
4 Apr 24